SYNTHETIC HUMAN PROLACTIN RECEPTOR, Product Type Purified Protein, Specificity PROLACTIN RECEPTOR, Target Species Human, Host N_A, Format Purified, Isotypes , Applications E, Clone
- Known as:
- SYNTHETIC HUMAN PROLACTIN RECEPTOR, Product Type Purified Protein, Specificity PROLACTIN RECEPTOR, Target Species Human, Host N_A, Format Purified, Isotypes , Applications E, Clone
- Catalog number:
- 7770-6020
- Product Quantity:
- 50 µg
- Category:
- -
- Supplier:
- AbD
- Gene target:
- SYNTHETIC HUMAN PROLACTIN RECEPTOR Product Type Purified Protein Specificity Target Species Human Host N_A Format Isotypes Applications Clone
Related genes to: SYNTHETIC HUMAN PROLACTIN RECEPTOR, Product Type Purified Protein, Specificity PROLACTIN RECEPTOR, Target Species Human, Host N_A, Format Purified, Isotypes , Applications E, Clone
- Gene:
- JAK3 NIH gene
- Name:
- Janus kinase 3
- Previous symbol:
- -
- Synonyms:
- L-JAK, JAKL, LJAK, JAK3_HUMAN, JAK-3
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-19
- Date modifiied:
- 2019-04-23
Related products to: SYNTHETIC HUMAN PROLACTIN RECEPTOR, Product Type Purified Protein, Specificity PROLACTIN RECEPTOR, Target Species Human, Host N_A, Format Purified, Isotypes , Applications E, Clone
Related articles to: SYNTHETIC HUMAN PROLACTIN RECEPTOR, Product Type Purified Protein, Specificity PROLACTIN RECEPTOR, Target Species Human, Host N_A, Format Purified, Isotypes , Applications E, Clone
- PANoptosis-related transcriptional programs may contribute to pediatric ulcerative colitis (UC), but the genes most consistently associated with disease activity and epithelial injury remain uncertain. - Source: PubMed
Dai HongDai LongfeiXu YufengLiu Xiaojing - Chronic hand dermatitis (CHD), also referred to as chronic hand eczema, is a persistent inflammatory skin disorder characterized by erythema, fissuring, scaling, lichenification, and significant pruritus and pain. The condition is often debilitating, particularly because the hands are constantly exposed to mechanical friction, detergents, irritants, and environmental stressors. Traditional treatments such as topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunomodulators are limited by safety concerns, incomplete efficacy, or poor long-term tolerability. Delgocitinib 2% cream, a non-steroidal, topical pan-Janus kinase (JAK) inhibitor, represents the first targeted therapy specifically approved for moderate-to-severe CHD in adults. Through inhibition of JAK1, JAK2, JAK3, and tyrosine kinase 2, delgocitinib broadly suppresses multiple cytokine pathways involved in hand eczema pathogenesis. Clinical trials have demonstrated significant improvement in Investigator's Global Assessment scores, Hand Eczema Severity Index, pruritus, pain, and quality of life, along with sustained benefit in long-term extension studies. Safety data reveal minimal systemic absorption, no steroid-associated skin atrophy, and a favorable tolerability profile without box warnings. This review examines the pathophysiology of CHD and the clinical evidence supporting delgocitinib as an effective, steroid-sparing therapeutic option. - Source: PubMed
Jani YashMiller Austinn - - Source: PubMed
Publication date: 2026/09/25
King BrettSoung JenniferTziotzios ChristosRudnicka LidiaJoly PascalGooderham MelindaSinclair RodneyMesinkovska Natasha APaul CarleGong YankunAnway Susan DTran HelenWolk RobertZwillich Samuel HLejeune Alexandre - JAK3 is a non-receptor tyrosine kinase that plays an important role in immune signaling pathways. It has long been indicated as a potential target for autoimmune diseases. In this work, a set of 28 novel JAK3 inhibitors were designed around a thieno[3,2-d]pyrimidine core, with aromatic moieties at the 2-position, and a range of alkyl linkers connected to electrophillic groups at the 4-position. Structure-based design has been employed in an attempt to maximize activity through direct reaction of the inhibitor electrophile and Cys909 residue located within the JAK3 active site. We identified the acrylamide containing compound 42 as a potent inhibitor of JAK3, with an IC of 6.2 nM and selectivity of 23.4-fold over the related JAK2 enzyme. This compares to 1.4 nM and 53.1-fold, respectively, for the 1st generation JAK3 inhibitor Tofacitinib. 42 also demonstrated good selectivity against 10 diverse kinases at a screening concentration of 1 μM, a low logD of 1.51 and good phosphate buffer solubility (1030.8 μg/ml). Computational analysis was undertaken to help rationalize the SAR in the form of molecular dynamics simulations and quantum chemical cluster calculations of electrophile-nucleophile reactivity. - Source: PubMed
Publication date: 2026/09/12
Fukasem PoowadonJaengwang KittitatGleeson DuangkamolBritton Robert GChoowongkomon KiattaweeGleeson M Paul - Phospholipase C (PLC)-evoked rising intracellular Ca2+-levels are a prerequisite for platelet activation with subsequent thrombosis. The protein-tyrosine kinase Janus kinase 3 (JAK3) regulates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2)-levels in platelets, thus significantly mediating activation-dependent platelet function and arterial thrombosis. - Source: PubMed
Publication date: 2026/09/21
Münzer PatrickKollotzek FerdinandManke Mailin-ChristinFindik BetülMott KristinaFischer MelinaLingens Gundula DZdanyte MonikaStein FredericGeue SaschaWalker BrittaGawaz MeinradGeisler TobiasRath DominikAhrends RobertLämmerhofer MichaelSchulze HaraldSkokowa JuliaBorst Oliver